Amgen, Novartis file dueling lawsuits over Aimovig collaboration by Eric Sagonowsky Thursday, April 4, 2019 Amgen wants to exit its collaboration with Novartis on migraine prevention drug Aimovig.
11. Amgen by Arlene Weintraub After two straight years at number 12 on FiercePharma’s list of the top pharma companies by revenues, Amgen moved up one spot with 2018 sales of $23.75 billion.
Teva forecasts tough year as generics hammer Copaxone by Arlene Weintraub Wednesday, February 13, 2019 Teva's Copaxone is losing ground to generic competition—and the company's newer drugs aren’t taking off fast enough to make up for the loss.
Teva migraine drug Ajovy sidelined by another PBM by Eric Sagonowsky Monday, February 4, 2019 UnitedHealthcare's pharmacy benefits outfit OptumRx picked Amgen and Eli Lilly CGRP drugs for its preferred coverage list, handing Teva a setback.
Botox can hold its own in growing migraine field, Allergan says by Eric Sagonowsky Thursday, January 31, 2019 Despite new competition from CGRP migraine prevention drugs, Allergan executives contend Botox can continue to grow.
CVS sidelines Amgen's Aimovig in favor of Teva, Lilly CGRP drugs by Eric Sagonowsky Monday, January 28, 2019 CVS' coverage decision for Amgen's Aimovig marks a setback for the company's launch and a boost for rivals Teva and Eli Lilly.
Rebounding Teva is ‘too cheap to ignore,' upbeat analysts say by Angus Liu Friday, February 8, 2019 What kind of difference can one year make? Just ask some Teva analysts, who are upbeat that the drugmaker's cost-cutting measures are paying off.
Cost watchdogs deal Novartis a blow with Aimovig rejection by Angus Liu Thursday, January 10, 2019 England's National Institute for Health and Care Excellence says available clinical data aren't enough to demonstrate Aimovig's cost-effectiveness.
Lilly's Emgality launch paving the way for a pain franchise: exec by Eric Sagonowsky Wednesday, January 9, 2019 Despite its CGRP drug Emgality's third-to-market status, Lilly has big plans for a growing stable of migraine and pain drugs, an exec said.
Lilly nets 'breakthrough' for CGRP Emgality by Eric Sagonowsky Thursday, November 15, 2018 The FDA has handed Lilly’s Emgality a 'breakthrough' nod in cluster headaches. Lilly plans to file for approval in that use by the end of the year.
